Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Hyunkyung | - |
dc.contributor.author | Kim, Hyeong-Joon | - |
dc.contributor.author | Sohn, Sang-Kyun | - |
dc.contributor.author | Baik, Yoonsuk | - |
dc.contributor.author | Kim, Dongho | - |
dc.contributor.author | Lee, Sung-Yeoun | - |
dc.contributor.author | Kong, Jee Hyun | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Ahn, Jae-Sook | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Park, Seonyang | - |
dc.contributor.author | Kim, Inho | - |
dc.date.accessioned | 2023-12-15T15:09:38Z | - |
dc.date.available | 2023-12-15T15:09:38Z | - |
dc.date.issued | 2023-11 | - |
dc.identifier.issn | 2040-6207 | - |
dc.identifier.issn | 2040-6215 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/89564 | - |
dc.description.abstract | Background: Droplet digital polymerase chain reaction (ddPCR) is an exact method of measurement.Objectives: We conducted this study to identify the prognostic factors for successful treatment-free remission in patients with chronic-phase chronic myeloid leukemia who discontinued tyrosine kinase inhibitors (TKIs). We also aimed to validate ddPCR for predicting molecular relapse.Design: This is a prospective, multicenter study.Methods: We enrolled patients treated with TKIs for at least 3 years with a confirmed sustained deep molecular response (DMR) for at least 1 year. TKI was re-administered in patients who experienced the loss of major molecular response (MMR).Results: A total of 66 patients from five institutions in South Korea were enrolled. During a median follow-up period of 16.5 months, 29/66 (43.9%) patients experienced molecular relapse; the probability of molecular relapse-free survival (RFS) at 6 or 12 months after TKI discontinuation was 65.6% or 57.8%, respectively, with most molecular relapses occurring within the first 7 months. All patients who lost MMR were re-treated with TKI, and all re-achieved MMR at a median of 2.8 months. E14a2 transcript type (p = 0.005) and longer DMR duration (>= 48 months) prior to TKI discontinuation (p = 0.002) were associated with prolonged molecular RFS and with sustained DMR. Patients with both e13a2 transcript type and detectable BCR::ABL1 (>= MR5.0) by ddPCR at the time of TKI discontinuation showed shorter duration of molecular RFS (p = 0.015).Conclusion: Our data suggest that transcript type and BCR::ABL1 transcript levels on ddPCR should be taken into consideration when deciding whether to discontinue TKI therapy. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.title | Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor | - |
dc.type | Article | - |
dc.identifier.wosid | 001096560800001 | - |
dc.identifier.doi | 10.1177/20406207231205637 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC ADVANCES IN HEMATOLOGY, v.14 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85176593263 | - |
dc.citation.title | THERAPEUTIC ADVANCES IN HEMATOLOGY | - |
dc.citation.volume | 14 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | chronic myeloid leukemia | - |
dc.subject.keywordAuthor | droplet digital polymerase chain reaction | - |
dc.subject.keywordAuthor | transcript type | - |
dc.subject.keywordAuthor | treatment-free remission | - |
dc.subject.keywordAuthor | tyrosine kinase inhibitor | - |
dc.subject.keywordPlus | CML PATIENTS | - |
dc.subject.keywordPlus | MOLECULAR RESPONSE | - |
dc.subject.keywordPlus | IMATINIB | - |
dc.subject.keywordPlus | RELAPSE | - |
dc.subject.keywordPlus | LONGER | - |
dc.subject.keywordPlus | E13A2 | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.